FPSUF(FPSUF)
FPSUF
10/15/26
Capha Pharmaceuticals (FPSUF)
Thursday
10:26 PM
ThesisThe company's operational struggles and negative cash flow are raising concerns among investors, overshadowing potential growth opportunities.
Revenue Outlook
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Rev. Growth | — | — |
| EPS | $-0.00 | $-0.00 |
| EPS Growth | +11.1% | -37.5% |
| P/E | — | — |
What Moves the Stock
- 01FDA approval of new oncology drugs
- 02Partnerships with larger pharmaceutical companies for distribution
- 03Changes in reimbursement policies affecting specialty drugs
- 04Market entry of competitive generic products
- 05Specialty pharmaceuticals - 100%
- 06Increased focus on personalized medicine in oncology
- 07Growing demand for specialty pharmaceuticals in emerging markets
FY2024 Snapshot
- Revenue
- $0.00
- Gross Margin
- 0.0%
- Op. Margin
- 0.0%
- Net Margin
- 0.0%
- Net Income
- $-70.8K
- NI Growth
- -32.6%
- EPS
- $-0.00
- 1Y Return
- +0.0%
FPSUF Chart
My Notes
- "Management acknowledged the need for a strategic overhaul to regain market confidence."
- Moat: Capha's focus on niche oncology markets provides some competitive advantage, but it is vulnerable to generic competition.
- value - Investors may be attracted to potential turnaround opportunities given the current low valuation.
- High interest rates could increase financing costs for R&D and operational expenses…
- Watch on earnings: FDA approval timelines for new drugs, Market share in oncology pharmaceuticals, R&D spending trends.
One Sentence Summary:
Capha Pharmaceuticals: the story is balanced — fda approval of new oncology drugs.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance
